ArticleBMC infectious diseases2026
Cohort evaluation of an all-oral shorter regimen for drug-resistant tuberculosis in Ecuador.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTuberculosis (TB) remains the leading cause of death from infectious agents globally and disproportionately affects people living with HIV. In 2023, 10.6 million TB cases were reported worldwide, including 8,200 in Ecuador. Between 2020 and 2023, TB incidence in Ecuador increased from 31.2 to 48.1 per 100,000 population, alongside rising rifampicin- and fluoroquinolone-resistant TB cases. Treatment success declined from 76.2% in 2019 to 69.2% in 2021, highlighting the need for more effective and patient-centered treatment strategies. This study evaluated the effectiveness, safety, and adherence of a nine-month all-oral shorter regimen compared with a standard injectable-based regimen and descriptively assessed outcomes of the BPaL regimen under routine programmatic conditions.
methodsWe conducted a cohort study across 61 health units in three cantons in Ecuador’s Zone 8: Guayaquil, Durán, and Samborondón. Between February 2020 and December 2022, 155 patients with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and nine with additional fluroquinolone-resistance were enrolled. Patients received either a nine-month all-oral shorter regimen comprising bedaquiline, linezolid, fluoroquinolones, and clofazimine (n = 98) or a standard nine-month injectable-based regimen (n = 57). Nine patients with fluroquinolone-resistant TB received the BpaL regimen. Treatment effectiveness, safety, and adherence were assessed using clinical and laboratory data.
resultsThe all-oral shorter regimen demonstrated higher effectiveness than the standard regimen (74% vs. 42%), along with lower mortality (4% vs. 7%), reduced loss to follow-up (20% vs. 47%), and higher adherence (93% vs. 79%). The BPaL regimen showed 89% effectiveness with 100% adherence. QTcF prolongation (Fridericia-corrected QT interval was the most frequent adverse event in the all-oral regimen but was generally mild.
conclusionsIn this programmatic cohort, the nine-month all-oral shorter and BPaL regimens were associated with favorable treatment outcomes, acceptable safety profiles, improved adherence, and reduced loss to follow-up compared with injectable-based therapy. These findings supported Ecuador’s adoption of the short all-oral regimen as the national standard for RR/MDR-TB treatment in 2024. Continued programmatic monitoring is essential to confirm sustained effectiveness and safety in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.